Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Veracyte Inc (NASDAQ: VCYT) closed at $33.46 down -14.99% from its previous closing price of $39.36. In other words, the price has decreased by -$14.99 from its previous closing price. On the day, 2.6 million shares were traded.
Ratios:
For a deeper understanding of Veracyte Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 40.64. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.73. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on December 05, 2024, Downgraded its rating to Neutral and sets its target price to $37 from $38 previously.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $50.
On October 16, 2024, UBS started tracking the stock assigning a Buy rating and target price of $43.UBS initiated its Buy rating on October 16, 2024, with a $43 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 03 ’25 when Chambers Rebecca sold 527 shares for $43.85 per share. The transaction valued at 23,109 led to the insider holds 113,510 shares of the business.
EASTHAM KARIN sold 10,000 shares of VCYT for $403,006 on Jan 02 ’25. The Director now owns 18,497 shares after completing the transaction at $40.30 per share. On Jan 02 ’25, another insider, KARIN EASTHAM, who serves as the Director of the company, bought 10,000 shares for $39.60 each.
Valuation Measures:
As of this moment, Veracyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 110.61, and their Forward P/E ratio for the next fiscal year is 39.75. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.82 while its Price-to-Book (P/B) ratio in mrq is 2.20.
Stock Price History:
Over the past 52 weeks, VCYT has reached a high of $47.32, while it has fallen to a 52-week low of $18.61. The 50-Day Moving Average of the stock is -20.17%, while the 200-Day Moving Average is calculated to be 2.62%.
Shares Statistics:
A total of 77.50M shares are outstanding, with a floating share count of 76.57M. Insiders hold about 1.20% of the company’s shares, while institutions hold 103.08% stake in the company.
